MDD

Overview of Major Depressive Disorder (MDD) in the United States

  • Total Population Context: Approximately 330,000,000330,000,000 people in the United States.

  • Demographic Focus: Individuals aged 1212 and older exhibit significant prevalence, specifically targeting adults aged 1818 to 2525.

  • Prevalence Statistics:

    • Approximately 11 in 66 Americans report symptoms of depression.

    • 19.1%19.1\% of women utilize prescription antidepressants.

  • Economic and Social Impact:

    • MDD is ranked 2nd2^{nd} on the global disability list.

    • The total economic burden of MDD is estimated at $380 billion\$380 \text{ billion}.

Clinical Characterization and Definition

  • Verbatim Definition: MDD is a "debilitating disease that is characterized by at least one discrete depressive episode lasting at least 2 weeks2 \text{ weeks} and involving clear-cut changes in mood, interests and pleasure, changes in cognition and vegetative symptoms."

  • Symptom Clustering: The symptoms characterizing a major depressive episode in MDD significantly overlap with the depressive symptoms observed in Schizophrenia and Bipolar Disorder.

  • Disability and Suicide Risk:

    • There is a high risk of disability associated with the disorder.

    • Suicide Statistics: Of the 800,000800,000 suicides occurring annually worldwide, approximately 50%50\% occur during a depressive episode.

    • Patients diagnosed with MDD are almost 2020-fold more likely to die by suicide compared to the general population.

Determinants of Major Depressive Disorder

  • Environmental Determinants (Consistent in both Men and Women):

    • Absence of a partner (due to factors such as divorce or widowhood).

    • Recent negative life events, including illness, the loss of close relatives or friends, financial problems, social problems, and unemployment.

  • Social Determinants:

    • Childhood Adversities: These are linked to higher symptom severity, a poorer disease course, and a higher rate of treatment non-response.

    • Socioeconomic Factors: Low socioeconomic status, low social support, and low educational attainment are key risk factors.

Disease Course and Prognosis

  • Predictors of Course: Higher symptom severity, psychiatric comorbidity, and a history of childhood trauma predict a less favorable disease course.

  • Population-Based Samples:

    • The mean duration of a single episode varies between 1313 and 30 weeks30 \text{ weeks}.

    • Approximately 70%70\% to 90%90\% of patients recover within 1 year1 \text{ year}.

  • Outpatient Care Settings (Less Favorable):

    • Only 25%25\% of patients achieve remission within 6 months6 \text{ months}.

    • Greater than 50%50\% of patients still meet the criteria for MDD after 2 years2 \text{ years}.

  • Remission and Recurrence:

    • Residual symptoms and functional impairments often persist even after remission.

    • 80%80\% of patients who achieve remittance will experience at least one recurrence during their lifetime.

Pathophysiology: Genetics and Environment

  • Genetic Factors:

    • First-degree relatives of MDD patients have a 33-fold increased risk of developing the disorder.

    • Heritability is quantified at approximately 35%35\%.

    • Genetic overlap exists with Schizophrenia and Bipolar Disorder.

    • The risk is highly polygenic, involving many genes that each contribute small effects.

  • Environmental Factors in Adulthood: Stressful events in the year preceding onset, such as loss of employment, financial insecurity, chronic or life-threatening health problems, exposure to violence, and separation.

  • Childhood Antecedents: Exposure to physical abuse, sexual abuse, and psychological neglect significantly increases the risk of later MDD.

Pathophysiology: HPA Axis and Neuroinflammation

  • Hypothalamic-Pituitary Axis (HPA): Early-life stress produces persistent increases in the activity of Corticotropin-Releasing Hormone (CRH)-containing neural circuits.

  • Clinical Studies on Abuse: Adults who experienced childhood sexual or physical abuse show markedly enhanced HPA axis activity when exposed to psychosocial stressors or endocrine tests designed to suppress HPA activity.

  • Glucocorticoid Resistance:

    • Glucocorticoid receptor function is reduced in these individuals.

    • Reduced receptor function leads to increased activation of the inflammatory system, which is normally under the physiological inhibitory control of cortisol.

    • Pathological triad: Glucocorticoid resistance, HPA axis hyperactivity, and increased inflammation are all evident in MDD.

Pathophysiology: Structural Brain Changes

  • MRI Findings: Structural MRI studies indicate that patients with MDD, compared to healthy controls, exhibit smaller brain volumes in the following regions:

    • Basal Ganglia

    • Thalamus

    • Hippocampus

    • Orbitofrontal Cortex

Psychotherapy Modalities

  • Cognitive-Behavioral Therapy (CBT): Focuses on teaching the patient to identify negative, distorted thinking patterns and provides skills to test and challenge these thoughts, replacing them with accurate positive ones.

  • Behavioral Activation Therapy: Focuses on increasing activities that provide pleasure or mastery and addresses avoidance processes.

  • Psychodynamic Therapy: Explores how emotions, thoughts, and early life experiences have created patterns contributing to current problems.

  • Problem-Solving Therapy: Teaches a structured set of skills to generate creative solutions for problems, overcome barriers, and make effective decisions.

  • Interpersonal Therapy: Helps patients resolve problems in relationships and social roles, such as conflicts, transitions, or relationship impoverishment.

  • Mindfulness-Based Therapy: Based on contemplative practices (primarily Buddhism); involves non-judgmental acceptance of thoughts and feelings through regular meditative practice.

Pharmacotherapy and Mechanism of Action

  • Classic Treatment Goal: Increasing monoamine levels in the brain.

  • Drug Classes and Examples:

    • Tricyclic Antidepressants (TCAs): Amitriptyline, Imipramine, Desipramine, Nortriptyline, Clomipramine, Trimipramine, Doxepin.

    • Selective Serotonin Reuptake Inhibitors (SSRIs): Sertraline, Fluoxetine, Paroxetine, Citalopram, Escitalopram, Fluvoxamine.

    • Selective Norepinephrine Reuptake Inhibitors (SNRIs): Venlafaxine, Duloxetine, Milnacipran, Desvenlafaxine, Levomilnacipran.

    • Monoamine Oxidase Inhibitors (MAOIs): Phenelzine, Tranylcypromine, Moclobemide.

    • Others/Multimodal: Vortioxetine, Vilazodone, Trazodone, Agomelatine, Mirtazapine, Mianserin, Reboxetine, Bupropion.

Neurotransmission Targets and Receptor Interactions

  • Transporters:

    • Serotonin Transporter (5-HTT): Targeted by Vortioxetine, Vilazodone, SSRIs, SNRIs, and TCAs.

    • Noradrenaline Transporter: Targeted by Reboxetine, Bupropion, SNRIs, and TCAs.

    • Dopamine Transporter: Targeted by Bupropion.

  • Presynaptic Targets:

    • MAO Enzyme: Inhibited by Phenelzine, Tranylcypromine, and Moclobemide.

    • 5−HT1A5-HT_{1A} Autoreceptor: Targeted by Vilazodone.

    • 5−HT1B5-HT_{1B} Autoreceptor: Targeted by Vortioxetine.

  • Postsynaptic and Diverse Receptors:

    • 5−HT25-HT_2 Receptors: Targeted by Trazodone, Agomelatine, Mirtazapine, Amitriptyline, Doxepin, and Mianserin.

    • α1\alpha_1-adrenergic and α2\alpha_2-adrenergic Receptors: Targeted by TCAs, Trazodone, Mirtazapine, and Mianserin.

    • H1H_1 (Histamine) Receptor: Targeted by Mirtazapine and Mianserin.

    • Muscarinic Acetylcholine Receptors: Targeted by TCAs (Amitriptyline, Clomipramine, Trimipramine, Doxepin).